Influence of Aliskiren on Albuminuria After Kidney Transplantation

Not Applicable

Completed

• Conditions: Albuminuria
• Interventions: Drug: aliskiren; Drug: losartan; Other: Placebo

• Registration Number: NCT02446548
• Lead Sponsor: Medical University of Gdansk

Brief Summary

The study is a randomised, double-blind, controlled 2 x 3 cross-over trial in which the renal effects of therapy with aliskiren (A), placebo (P) and losartan (L) will be compared. It consists of an 8-week run-in period, 8 weeks of active treatment with aliskiren or losartan (period 1), 8 weeks of active treatment with the alternative medication (period 2), and an 8-week placebo administration between them.

Detailed Description

At the beginning, subjects who met the inclusion criteria will enter the 8-week run-in screening period. All hypotensive group of drugs will be allowed with exception of ACEI, ARA, DRI and mineralocorticoid receptor antagonists. The target BP will be an office trough BP of 140/90 mmHg or less. At the end of the run-in period, patients will be randomly allocated to one of the two treatment sequences: L/P/A (sequence 1) or A/P/L (sequence 2) . The study medications will be introduced as single hypotensive drug or added to the current hypotensive agents, the dosage of which, once adjusted in the run-in period, will be left unchanged throughout the study. Losartan will be used at a dose of 50 mg and aliskiren will be administered at a dose of 150 mg. Drug compliance will be assessed by tablet counts. Patients will be recommended not to change their usual daily protein and sodium intake during the study period. Dosage of cyclosporine or tacrolimus will be not allowed to change either. At the end of each of the three treatment periods, office thorough BP, 24-h ambulatory BP, albuminuria, serum creatinine and potassium, haemoglobin, cyclosporine or tacrolimus level, urine excretion of NAG, TGF-β-1 and 15-F2t-isoprostanes will be determined. eGFR will be calculated. Patients will be also asked to fill in the questionnaire for measuring patients-reported side effects.

Study Timeline

• Study Start: 2013-03
• Primary Completion: 2014-04
• Study Completion: 2014-11
• Status Verified: 2015-05
• Study First Submitted: 2015-05-08
• Study First Submitted QC: 2015-05-13
• Last Update Submitted: 2015-05-13
• Study First Posted: 2015-05-18
• Last Update Posted: 2015-05-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

1. Transplantation period above 6 months,
2. Calcineurin inhibitor (cyclosporine or tacrolimus) based immunosuppression,
3. Stable cyclosporine or tacrolimus trough level in the last three months (no variations above 25%),
4. Stable renal function defined as eGFR > 30 ml/min (no variations above 5 ml/min/1.73 m2 in the last 3 months),
5. Arterial hypertension treated with one or two antihypertensive agents or blood pressure (BP) > 130/80 mmHg in patients not treated yet,
6. Albuminuria > 30 mg/g creatinine.

Exclusion Criteria

1. Pregnant or the possibility of becoming so and breast feeding.
2. Angioedema from an ACE inhibitor or ARA in the history.
3. Serum potassium greater than 5.5 mmol/l on two or more occasions in the preceding three months.
4. Graft artery stenosis (i.e. psv of more than 200 cm/s in doppler usg)
5. Left ventricular dysfunction that requires an ACE inhibitor or an ARA Protocol Version 1 p. 5 of 10
6. New immunosuppressive agent was started or previous immunosuppressant stopped in the three months prior to study entry or plan to switch immunosuppressive agents within next three months.
7. Currently on four or more blood pressure pills and have an average blood pressure over three visits greater than 150/100.
8. Currently on an ACE-inhibitor or an ARAor treatment with an ACE inhibitor or ARA after kidney transplantation lasted more than 3 months.
9. Had an acute coronary syndrome, episode of malignant hypertension, stroke or transient ischaemic attack in the three months prior to study entry

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
losartan - placebo - aliskiren	Placebo	aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
aliskiren - placebo - losartan	Placebo	aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
losartan - placebo - aliskiren	aliskiren	aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
aliskiren - placebo - losartan	aliskiren	aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
aliskiren - placebo - losartan	losartan	aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
losartan - placebo - aliskiren	losartan	aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg

Primary Outcome Measures

Name	Time	Method
a difference in albuminuria in the measurements available for each patient	after 8 weeks of treatment

Secondary Outcome Measures

Name	Time	Method
a differences in N-acetyl-β-D-glucosaminidase (NAG) urine excretion in the measurements available for each patient	after 8 weeks of treatment
a differences in transforming growth factor β-1 (TGF-β-1) urine excretion in the measurements available for each patient	after 8 weeks of treatment
a differences in 15-F2t-isoprostanes (isoprostanes) urine excretion in the measurements available for each patient	after 8 weeks of treatment

Trial Locations

Locations (1)

Medical University of Gdansk; 🇵🇱 Gdansk, Pomorskie, Poland